- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT06133972
Fas 3 förlängningsstudie för att utvärdera långsiktig säkerhet för Ianalumab hos deltagare med systemisk lupus erythematosus (SIRIUS-SLE-förlängning). (SIRIUS-SLE LTE)
A Randomized, Double-blind, Placebo-controlled Extension Study, Followed by a Study Treatment Withdrawal or Open-label Period, to Assess the Long-term Safety and Tolerability of Ianalumab in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE Extension)
The purpose of this study is to evaluate long-term safety and tolerability of ianalumab in participants with systemic lupus erythematosus who have previously completed the treatment period in one of the two SIRIUS-SLE core studies (CVAY736F12301 or CVAY736F12302).
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
The purpose of this extension study is to evaluate long-term safety and tolerability of ianalumab administered s.c. monthly or quarterly, compared to monthly placebo, in adolescent and adult participants with anti-nuclear antibody (ANA)-positive systemic lupus erythematosus of moderate-to-severe disease activity, who have completed either CVAY736F12301 (SIRIUS-SLE 1) or CVAY736F12302 (SIRIUS-SLE 2) core studies.
This extension study will last up to 7 years and includes the following three treatment periods:
- a 3-year double-blind, randomized, placebo-controlled treatment period, evaluating the safety and efficacy of ianalumab or placebo (Period 1);
- followed by a 2-year treatment period evaluating safety and efficacy of treatment withdrawal and open-label ianalumab administered s.c. monthly.
- and an up to 2-year open-label, safety monitoring period (Period 3).
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 3
Utökad åtkomst
Kontakter och platser
Studiekontakt
- Namn: Novartis Pharmaceuticals
- Telefonnummer: 1-888-669-6682
- E-post: novartis.email@novartis.com
Studera Kontakt Backup
- Namn: Novartis Pharmaceuticals
- Telefonnummer: +41613241111
- E-post: novartis.email@novartis.com
Studieorter
-
-
-
Caba, Argentina, C1015ABO
- Aktiv, inte rekryterande
- Novartis Investigative Site
-
Caba, Argentina, C1427CCL
- Rekrytering
- Novartis Investigative Site
-
San Miguel de Tucumán, Argentina, T4000AXL
- Aktiv, inte rekryterande
- Novartis Investigative Site
-
-
Buenos Aires
-
La Plata, Buenos Aires, Argentina, B1900AWT
- Rekrytering
- Novartis Investigative Site
-
Quilmes, Buenos Aires, Argentina, 1878
- Rekrytering
- Novartis Investigative Site
-
San Miguel, Buenos Aires, Argentina, B1663GKT
- Aktiv, inte rekryterande
- Novartis Investigative Site
-
-
Tucumán Province
-
San Miguel, Tucumán Province, Argentina, T4000CBC
- Aktiv, inte rekryterande
- Novartis Investigative Site
-
-
-
-
Queensland
-
Maroochydore, Queensland, Australien, 4558
- Rekrytering
- Novartis Investigative Site
-
-
-
-
-
Salvador, Brasilien, 40323-010
- Rekrytering
- Novartis Investigative Site
-
-
Espírito Santo
-
Vitória, Espírito Santo, Brasilien, 29055-450
- Rekrytering
- Novartis Investigative Site
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, Brasilien, 40150-150
- Rekrytering
- Novartis Investigative Site
-
-
Minas Gerais
-
Belo Horizonte, Minas Gerais, Brasilien, 30150-221
- Aktiv, inte rekryterande
- Novartis Investigative Site
-
-
Paraná
-
Curitiba, Paraná, Brasilien, 80030-110
- Rekrytering
- Novartis Investigative Site
-
-
Rio de Janeiro
-
Niterói, Rio de Janeiro, Brasilien, 24020-096
- Aktiv, inte rekryterande
- Novartis Investigative Site
-
Rio de Janeiro, Rio de Janeiro, Brasilien, 22211-230
- Rekrytering
- Novartis Investigative Site
-
-
São Paulo
-
Barretos, São Paulo, Brasilien, 14784-400
- Rekrytering
- Novartis Investigative Site
-
São Paulo, São Paulo, Brasilien, 04038-002
- Aktiv, inte rekryterande
- Novartis Investigative Site
-
São Paulo, São Paulo, Brasilien, 01244-030
- Aktiv, inte rekryterande
- Novartis Investigative Site
-
-
-
-
-
Sofia, Bulgarien, 1431
- Rekrytering
- Novartis Investigative Site
-
-
Bulgaria
-
Plovdiv, Bulgaria, Bulgarien, 4002
- Rekrytering
- Novartis Investigative Site
-
-
-
-
Los Ríos Region
-
Valdivia, Los Ríos Region, Chile, 5110683
- Rekrytering
- Novartis Investigative Site
-
-
RM
-
Santiago, RM, Chile, 7500588
- Rekrytering
- Novartis Investigative Site
-
-
Santiago Metropolitan
-
Santiago, Santiago Metropolitan, Chile, 7500710
- Rekrytering
- Novartis Investigative Site
-
-
-
-
-
Bogotá, Colombia, 111211
- Aktiv, inte rekryterande
- Novartis Investigative Site
-
-
Antioquia
-
Medellín, Antioquia, Colombia, 050001
- Aktiv, inte rekryterande
- Novartis Investigative Site
-
-
Atlántico
-
Barranquilla, Atlántico, Colombia, 080020
- Aktiv, inte rekryterande
- Novartis Investigative Site
-
-
Cundinamarca
-
Chía, Cundinamarca, Colombia, 250001
- Aktiv, inte rekryterande
- Novartis Investigative Site
-
-
Santander Department
-
Bucaramanga, Santander Department, Colombia, 680003
- Aktiv, inte rekryterande
- Novartis Investigative Site
-
-
Valle del Cauca Department
-
Cali, Valle del Cauca Department, Colombia, 760046
- Rekrytering
- Novartis Investigative Site
-
-
-
-
-
Montpellier, Frankrike, 34295
- Rekrytering
- Novartis Investigative Site
-
Paris, Frankrike, 75014
- Aktiv, inte rekryterande
- Novartis Investigative Site
-
Paris, Frankrike, 75013
- Aktiv, inte rekryterande
- Novartis Investigative Site
-
Toulouse, Frankrike, 31059
- Rekrytering
- Novartis Investigative Site
-
Toulouse, Frankrike, 31054
- Rekrytering
- Novartis Investigative Site
-
-
-
-
Alabama
-
Anniston, Alabama, Förenta staterna, 36207
- Rekrytering
- Pinnacle Research Group Llc
-
Huvudutredare:
- Vishala L Chindalore
-
Kontakt:
- Ruby Fields
- Telefonnummer: +1 256 236 0055
- E-post: rfields@pinnacletrials.com
-
-
California
-
Burbank, California, Förenta staterna, 91505
- Rekrytering
- Providence Medical Center
-
Huvudutredare:
- Sue Chung
-
Kontakt:
- Sandra Figueroa
- Telefonnummer: +1 818 869 7067
- E-post: Sandra.Figueroa@providence.org
-
La Palma, California, Förenta staterna, 90623
- Rekrytering
- Advanced Medical Research
-
Huvudutredare:
- Gerald Ho
-
Kontakt:
- Reza Azadegan
- Telefonnummer: +1 714 752 6587
- E-post: razadegan@advmedresearch.com
-
Westlake Village, California, Förenta staterna, 91361
- Aktiv, inte rekryterande
- Millennium Clinical Trials
-
-
Colorado
-
Aurora, Colorado, Förenta staterna, 80045
- Rekrytering
- University of Colorado Denver
-
Huvudutredare:
- Christopher Striebich
-
Kontakt:
- Chong Pedrick
- E-post: chong.pedrick@cuanschutz.edu
-
-
Florida
-
Clearwater, Florida, Förenta staterna, 33765
- Rekrytering
- Clinical Res Of W Florida
-
Huvudutredare:
- Robert Levin
-
Kontakt:
- Jessica Mayfield
- Telefonnummer: +1 727 466 0078
- E-post: JMayfield@crwf.com
-
Cooper City, Florida, Förenta staterna, 33024
- Rekrytering
- GNP Research
-
Huvudutredare:
- Mark Jaffe
-
Kontakt:
- Melissa Pierce
- Telefonnummer: +1 754 248 3589
- E-post: melissa@gnpresearch.com
-
Homestead, Florida, Förenta staterna, 33033
- Rekrytering
- Homestead Assoc In Research Inc
-
Huvudutredare:
- Gilberto Seco
-
Kontakt:
- Mario Hernandez
- Telefonnummer: 13052460873
- E-post: mhernandez@associatesinresearch.com
-
Plantation, Florida, Förenta staterna, 33324
- Rekrytering
- IRIS Research and Development
-
Huvudutredare:
- Guillermo Valenzuela
-
Kontakt:
- Jhon Galindo
- Telefonnummer: +1 954 476 2338
- E-post: jgalindo@irisrheumatology.com
-
Tampa, Florida, Förenta staterna, 33603
- Rekrytering
- Clinical Research of West Florida Inc
-
Huvudutredare:
- John Carter
-
Kontakt:
- Abby Carlson
- Telefonnummer: +1 813 870 1292
- E-post: ACarlson@crwf.com
-
-
Georgia
-
Lawrenceville, Georgia, Förenta staterna, 30044
- Rekrytering
- Parris and Associates Rheumatology
-
Huvudutredare:
- Glenn Parris
-
Kontakt:
- Mannai Coutermarsh
- Telefonnummer: +17709621616#8334
- E-post: m.coutermarsh@parrisandassociates.net
-
-
Illinois
-
Skokie, Illinois, Förenta staterna, 60076
- Avslutad
- Robert A Hozman MD SC
-
Willowbrook, Illinois, Förenta staterna, 60527
- Rekrytering
- Willow Rheumatology Wellness
-
Huvudutredare:
- Angela R Crowley
-
Kontakt:
- Lubna Ali
- E-post: lali@willowrheum.com
-
-
Louisiana
-
Lake Charles, Louisiana, Förenta staterna, 70601
- Rekrytering
- Accurate Clinical Research
-
Huvudutredare:
- Enrique Mendez
-
Kontakt:
- Machell Broussard
- E-post: mbroussard@accurateclinicalresearch.com
-
New Orleans, Louisiana, Förenta staterna, 70112
- Aktiv, inte rekryterande
- UMC New Orleans
-
-
Maryland
-
Baltimore, Maryland, Förenta staterna, 21201
- Aktiv, inte rekryterande
- University Of Maryland
-
-
Michigan
-
Detroit, Michigan, Förenta staterna, 48202
- Rekrytering
- Henry Ford Health
-
Huvudutredare:
- Alireza Meysami
-
Kontakt:
- Jenna Hudy
- Telefonnummer: +1 313 916 1984
- E-post: jhudy1@hfhs.org
-
Grand Blanc, Michigan, Förenta staterna, 48439
- Rekrytering
- Ahmed Arif Medical Research Center
-
Huvudutredare:
- Ali Karrar
-
Kontakt:
- Iman Abdelrahman
- Telefonnummer: +1 810 953 8700
- E-post: iman@aamrc.net
-
-
Ohio
-
Middleburg Heights, Ohio, Förenta staterna, 44130
- Rekrytering
- Paramount Med Rsrch and Consult LLC
-
Huvudutredare:
- Isam Diab
-
Kontakt:
- Denine Ryan
- Telefonnummer: +1 440 891 9395
- E-post: deniner64@gmail.com
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Förenta staterna, 15213
- Rekrytering
- University Of Pittsburgh
-
Huvudutredare:
- Andreea Coca
-
Kontakt:
- Kathryn Lemon
- E-post: kal128@pitt.edu
-
-
Tennessee
-
Jackson, Tennessee, Förenta staterna, 38305
- Rekrytering
- West Tennessee Research Institute
-
Huvudutredare:
- Jacob A Aelion
-
Kontakt:
- Rachel Williams
- Telefonnummer: 17316330119
- E-post: rwilliams@arthritisclinic.org
-
Memphis, Tennessee, Förenta staterna, 38119
- Rekrytering
- Shelby Research LLC
-
Huvudutredare:
- Ramesh C Gupta
-
Kontakt:
- Suvarna Konangula
- Telefonnummer: +1 901 681 9670
- E-post: shelbyres1999@outlook.com
-
-
Texas
-
Bellaire, Texas, Förenta staterna, 77401
- Rekrytering
- Novel Research LLC
-
Huvudutredare:
- Wajeeha Yousaf
-
Kontakt:
- Hassan Khan
- E-post: khan@novelresearch.net
-
League City, Texas, Förenta staterna, 77573
- Rekrytering
- Accurate Clinical Research
-
Huvudutredare:
- Sabeen Najam
-
Kontakt:
- Mariela Martinez
- Telefonnummer: +1 281 422 7179
- E-post: mmartinez@accurateclinicalresearch.com
-
Red Oak, Texas, Förenta staterna, 75154
- Rekrytering
- Epic Medical Research
-
Huvudutredare:
- Sunny Patel
-
Kontakt:
- Harshini Potluri
- Telefonnummer: +1 469 206 2642
- E-post: hpotluri@epicmedresearch.com
-
-
-
-
-
Guatemala City, Guatemala, 01010
- Rekrytering
- Novartis Investigative Site
-
-
Departamento de Guatemala
-
Guatemala City, Departamento de Guatemala, Guatemala, 01010
- Rekrytering
- Novartis Investigative Site
-
-
-
-
-
New Delhi, Indien, 110075
- Rekrytering
- Novartis Investigative Site
-
-
Gujarat
-
Ahmedabad, Gujarat, Indien, 380015
- Rekrytering
- Novartis Investigative Site
-
Ahmedabad, Gujarat, Indien, 380006
- Rekrytering
- Novartis Investigative Site
-
-
Kerala
-
Kozhikode, Kerala, Indien, 673008
- Rekrytering
- Novartis Investigative Site
-
-
Maharashtra
-
Kolhāpur, Maharashtra, Indien, 416001
- Rekrytering
- Novartis Investigative Site
-
Nagpur, Maharashtra, Indien, 441108
- Rekrytering
- Novartis Investigative Site
-
Nashik, Maharashtra, Indien, 422101
- Rekrytering
- Novartis Investigative Site
-
Pune, Maharashtra, Indien, 411001
- Rekrytering
- Novartis Investigative Site
-
Pune, Maharashtra, Indien, 411007
- Rekrytering
- Novartis Investigative Site
-
-
National Capital Territory of Delhi
-
New Delhi, National Capital Territory of Delhi, Indien, 110060
- Rekrytering
- Novartis Investigative Site
-
-
New Delhi
-
New Delhi, New Delhi, Indien, 110029
- Rekrytering
- Novartis Investigative Site
-
-
Uttarakhand
-
Dehradun, Uttarakhand, Indien, 248001
- Rekrytering
- Novartis Investigative Site
-
-
-
-
-
Haifa, Israel, 3109601
- Aktiv, inte rekryterande
- Novartis Investigative Site
-
Ramat Gan, Israel, 5265601
- Rekrytering
- Novartis Investigative Site
-
-
-
-
FE
-
Cona, FE, Italien, 44124
- Rekrytering
- Novartis Investigative Site
-
-
PD
-
Padova, PD, Italien, 35128
- Rekrytering
- Novartis Investigative Site
-
-
PI
-
Pisa, PI, Italien, 56126
- Rekrytering
- Novartis Investigative Site
-
-
RM
-
Roma, RM, Italien, 00152
- Rekrytering
- Novartis Investigative Site
-
-
TO
-
Torino, TO, Italien, 10128
- Rekrytering
- Novartis Investigative Site
-
-
-
-
-
Miyazaki, Japan, 8891692
- Rekrytering
- Novartis Investigative Site
-
Osaka, Japan, 5458586
- Rekrytering
- Novartis Investigative Site
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Japan, 4578510
- Aktiv, inte rekryterande
- Novartis Investigative Site
-
Nagoya, Aichi-ken, Japan, 4578511
- Aktiv, inte rekryterande
- Novartis Investigative Site
-
-
Hokkaido
-
Sapporo, Hokkaido, Japan, 0608648
- Aktiv, inte rekryterande
- Novartis Investigative Site
-
-
Kanagawa
-
Yokohama, Kanagawa, Japan, 2360004
- Aktiv, inte rekryterande
- Novartis Investigative Site
-
-
Miyagi
-
Sendai, Miyagi, Japan, 9838512
- Rekrytering
- Novartis Investigative Site
-
-
Tokyo
-
Bunkyo-ku, Tokyo, Japan, 1138519
- Rekrytering
- Novartis Investigative Site
-
Chuo Ku, Tokyo, Japan, 1048560
- Rekrytering
- Novartis Investigative Site
-
Fuchū, Tokyo, Japan, 1838524
- Aktiv, inte rekryterande
- Novartis Investigative Site
-
Shinjuku-ku, Tokyo, Japan, 1608582
- Aktiv, inte rekryterande
- Novartis Investigative Site
-
tabashi City, Tokyo, Japan, 1738610
- Aktiv, inte rekryterande
- Novartis Investigative Site
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Kanada, V5Z 1L7
- Aktiv, inte rekryterande
- Novartis Investigative Site
-
-
Ontario
-
Toronto, Ontario, Kanada, M5T 2S8
- Aktiv, inte rekryterande
- Novartis Investigative Site
-
-
Quebec
-
Rimouski, Quebec, Kanada, G5L 5T1
- Rekrytering
- Novartis Investigative Site
-
-
-
-
-
Beijing, Kina, 100730
- Rekrytering
- Novartis Investigative Site
-
Beijing, Kina, 100069
- Rekrytering
- Novartis Investigative Site
-
Shanghai, Kina, 200001
- Rekrytering
- Novartis Investigative Site
-
Xinxiang, Kina, 453099
- Rekrytering
- Novartis Investigative Site
-
-
Guangdong
-
Guangzhou, Guangdong, Kina, 510080
- Rekrytering
- Novartis Investigative Site
-
Guangzhou, Guangdong, Kina, 510000
- Rekrytering
- Novartis Investigative Site
-
Shantou, Guangdong, Kina, 515000
- Rekrytering
- Novartis Investigative Site
-
-
Jiangsu
-
Nanjing, Jiangsu, Kina, 210008
- Rekrytering
- Novartis Investigative Site
-
Suzhou, Jiangsu, Kina, 215004
- Rekrytering
- Novartis Investigative Site
-
-
Jiangxi
-
Nanchang, Jiangxi, Kina, 330006
- Aktiv, inte rekryterande
- Novartis Investigative Site
-
Pingxiang, Jiangxi, Kina, 337000
- Rekrytering
- Novartis Investigative Site
-
-
Jilin
-
Changchun, Jilin, Kina, 130021
- Rekrytering
- Novartis Investigative Site
-
-
Shandong
-
Linyi, Shandong, Kina, 276100
- Rekrytering
- Novartis Investigative Site
-
-
Sichuan
-
Chengdu, Sichuan, Kina, 610041
- Rekrytering
- Novartis Investigative Site
-
-
Xinjiang
-
Ürümqi, Xinjiang, Kina, 830001
- Rekrytering
- Novartis Investigative Site
-
-
Zhejiang
-
Ningbo, Zhejiang, Kina, 315016
- Rekrytering
- Novartis Investigative Site
-
Wenzhou, Zhejiang, Kina, 325000
- Rekrytering
- Novartis Investigative Site
-
-
-
-
Perak
-
Ipoh, Perak, Malaysia, 30450
- Rekrytering
- Novartis Investigative Site
-
-
-
-
-
México, Mexiko, 07760
- Aktiv, inte rekryterande
- Novartis Investigative Site
-
-
Guanajuato
-
León, Guanajuato, Mexiko, 37160
- Rekrytering
- Novartis Investigative Site
-
-
Jalisco
-
Guadalajara, Jalisco, Mexiko, 44160
- Aktiv, inte rekryterande
- Novartis Investigative Site
-
-
Mexico City
-
Mexico City, Mexico City, Mexiko, 06700
- Aktiv, inte rekryterande
- Novartis Investigative Site
-
-
Michoacán
-
Morelia, Michoacán, Mexiko, 58000
- Aktiv, inte rekryterande
- Novartis Investigative Site
-
-
Yucatán
-
Mérida, Yucatán, Mexiko, 97070
- Rekrytering
- Novartis Investigative Site
-
-
-
-
-
Bydgoszcz, Polen, 85-065
- Rekrytering
- Novartis Investigative Site
-
Bydgoszcz, Polen, 85-168
- Rekrytering
- Novartis Investigative Site
-
Bytom, Polen, 41 902
- Rekrytering
- Novartis Investigative Site
-
Warsaw, Polen, 00-874
- Rekrytering
- Novartis Investigative Site
-
Warsaw, Polen, 04-141
- Rekrytering
- Novartis Investigative Site
-
-
Lower Silesian Voivodeship
-
Wroclaw, Lower Silesian Voivodeship, Polen, 52-210
- Rekrytering
- Novartis Investigative Site
-
-
-
-
-
Braga, Portugal, 4710-243
- Rekrytering
- Novartis Investigative Site
-
Lisbon, Portugal, 1050-034
- Rekrytering
- Novartis Investigative Site
-
-
-
-
-
Brasov, Rumänien, 500283
- Rekrytering
- Novartis Investigative Site
-
Bucharest, Rumänien, 011172
- Rekrytering
- Novartis Investigative Site
-
-
Cluj
-
Cluj-Napoca, Cluj, Rumänien, 400006
- Rekrytering
- Novartis Investigative Site
-
-
-
-
-
Bratislava, Slovakien, 811 08
- Aktiv, inte rekryterande
- Novartis Investigative Site
-
Košice, Slovakien, 040 01
- Aktiv, inte rekryterande
- Novartis Investigative Site
-
-
-
-
-
Barcelona, Spanien, 08035
- Rekrytering
- Novartis Investigative Site
-
Madrid, Spanien, 28034
- Rekrytering
- Novartis Investigative Site
-
Valencia, Spanien, 46014
- Rekrytering
- Novartis Investigative Site
-
-
A Coruna
-
Santiago Compostela, A Coruna, Spanien, 15706
- Rekrytering
- Novartis Investigative Site
-
-
Barcelona
-
Badalona, Barcelona, Spanien, 08916
- Rekrytering
- Novartis Investigative Site
-
-
Cantabria
-
Santander, Cantabria, Spanien, 39008
- Rekrytering
- Novartis Investigative Site
-
-
Catalonia
-
Barcelona, Catalonia, Spanien, 08003
- Rekrytering
- Novartis Investigative Site
-
-
Madrid
-
San Sebastian Reyes, Madrid, Spanien, 28702
- Rekrytering
- Novartis Investigative Site
-
-
-
-
-
Umhlanga, Sydafrika, 4320
- Rekrytering
- Novartis Investigative Site
-
-
Gauteng
-
Pretoria, Gauteng, Sydafrika, 0002
- Rekrytering
- Novartis Investigative Site
-
-
Western Cape
-
Cape Town, Western Cape, Sydafrika, 7500
- Rekrytering
- Novartis Investigative Site
-
Cape Town, Western Cape, Sydafrika, 7405
- Rekrytering
- Novartis Investigative Site
-
Somerset West, Western Cape, Sydafrika, 7130
- Rekrytering
- Novartis Investigative Site
-
-
-
-
-
Gwangju, Sydkorea, 61469
- Avslutad
- Novartis Investigative Site
-
Seoul, Sydkorea, 06591
- Rekrytering
- Novartis Investigative Site
-
Seoul, Sydkorea, 04763
- Rekrytering
- Novartis Investigative Site
-
-
-
-
-
Kaohsiung City, Taiwan, 833
- Rekrytering
- Novartis Investigative Site
-
Taichung, Taiwan, 40447
- Rekrytering
- Novartis Investigative Site
-
Taichung, Taiwan, 407219
- Rekrytering
- Novartis Investigative Site
-
Taipei, Taiwan, 10002
- Rekrytering
- Novartis Investigative Site
-
Taipei, Taiwan, 11217
- Rekrytering
- Novartis Investigative Site
-
Taoyuan, Taiwan, 33305
- Rekrytering
- Novartis Investigative Site
-
-
-
-
-
Bangkok, Thailand, 10400
- Rekrytering
- Novartis Investigative Site
-
Bangkok, Thailand, 10700
- Rekrytering
- Novartis Investigative Site
-
-
Hat Yai
-
Songkhla, Hat Yai, Thailand, 90110
- Rekrytering
- Novartis Investigative Site
-
-
Thailand
-
Muang, Thailand, Thailand, 12120
- Rekrytering
- Novartis Investigative Site
-
-
-
-
-
Brno, Tjeckien, 638 00
- Rekrytering
- Novartis Investigative Site
-
Prague, Tjeckien, 128 00
- Rekrytering
- Novartis Investigative Site
-
Uherské Hradiště, Tjeckien, 686 01
- Rekrytering
- Novartis Investigative Site
-
-
-
-
North Rhine-Westphalia
-
Cologne, North Rhine-Westphalia, Tyskland, 50937
- Indragen
- Novartis Investigative Site
-
-
Saxony
-
Leipzig, Saxony, Tyskland, 04103
- Rekrytering
- Novartis Investigative Site
-
-
-
-
-
Budapest, Ungern, 1134
- Rekrytering
- Novartis Investigative Site
-
Gyula, Ungern, 5700
- Rekrytering
- Novartis Investigative Site
-
Zalaegerszeg, Ungern, 8900
- Rekrytering
- Novartis Investigative Site
-
-
Fejér
-
Székesfehérvár, Fejér, Ungern, 8000
- Rekrytering
- Novartis Investigative Site
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Key Inclusion Criteria:
- Signed informed consent prior to participation in the extension study. Parent or legal guardian's signed informed consent and child's assent, if appropriate, are required before any assessment is performed for participants <18 years of age. Of note, if the participant reaches age of consent (age as per local law) during the study, they will also need to sign the corresponding study Informed Consent Form (ICF) at the next study visit.
- Participants must have participated in either one of the two SIRIUS-SLE core studies, CVAY736F12301 or CVAY736F12302, and have completed the treatment period through Week 60 without treatment discontinuation.
- In the judgement of the investigator, participants must be expected to clinically benefit from continued study treatment.
Key Exclusion Criteria:
- Use of prohibited therapies.
- Active viral, bacterial or other infections requiring intravenous or intramuscular treatment for clinically significant infection which in the opinion of the investigator will place the participant at risk for participation.
- Plans for administration of live vaccines during the study period.
- Pregnant or nursing (lactating) women.
Other protocol-defined inclusion/exclusion criteria may apply.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Ianalumab monthly
Ianalumab s.c. monthly |
Ianalumab s.c. monthly Ianalumab s.c. quarterly
Andra namn:
|
|
Experimentell: Ianalumab quarterly
Ianalumab s.c. quarterly |
Ianalumab s.c. monthly Ianalumab s.c. quarterly
Andra namn:
|
|
Placebo-jämförare: Placebo monthly
Placebo s.c. monthly |
Placebo s.c. monthly |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Number of treatment-emergent Adverse events/Serious Adverse events
Tidsram: through study completion, up to approximately 324 weeks
|
Assessment of long-term safety and tolerability of ianalumab |
through study completion, up to approximately 324 weeks
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Proportion of participants who achieved Systemic Lupus Erythematosus Responder Index -4 (SRI-4) response
Tidsram: up to Week 324
|
SRI-4 response is defined as:
|
up to Week 324
|
|
Proportion of participants who achieved Definition of Remission in SLE (DORIS) response
Tidsram: up to Week 324
|
DORIS is defined as:
|
up to Week 324
|
|
Change in Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index
Tidsram: up to Week 324
|
SLICC/ACR Damage Index is a measure of cumulative damage due to SLE |
up to Week 324
|
|
Average daily dose of corticosteroids administered
Tidsram: up to Week 324
|
Evaluating the effect of ianalumab on corticosteroids intake |
up to Week 324
|
|
Annualized BILAG moderate or severe flare rate
Tidsram: up to Week 324
|
Annualized BILAG moderate or severe flare rate where moderate BILAG flare is defined as 2 or more new BILAG-2004 B items, and severe BILAG flare is defined as 1 or more new BILAG-2004 A items, compared to the previous visit |
up to Week 324
|
|
Ianalumab serum concentrations during treatment and follow-up after last dose
Tidsram: up to Week 324
|
To characterize the Pharmacokinetics (PK) of ianalumab |
up to Week 324
|
|
Incidence and titer of anti-ianalumab antibodies in serum (ADA assay) over time.
Tidsram: up to Week 324
|
To characterize the immunogenicity of ianalumab |
up to Week 324
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- CVAY736F12301E1
- 2023-505929-14-00 (Registeridentifierare: EU CT NUMBER)
- 2023 (U.S.S. NIH-anslag/kontrakt)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .